Aspire Biopharma Holdings, Inc.

Aspire Biopharma Holdings, Inc., trading under the ticker PWUP, filed its annual report on Form 10-K with the U.S. Securities and Exchange Commission on April 7, 2025, covering the fiscal year ended December 31, 2024. The company is a biopharmaceutical holding entity that reached the public markets through a SPAC business combination, operating within the life sciences and drug development sector. The 10-K reflects Aspire Biopharma Holdings' ongoing reporting obligations as a post-combination public company following its de-SPAC transaction. PWUP was originally structured as a blank check company before completing its merger with the biopharma operating business. For full filing history, sponsor details, and deal-level analytics on PWUP, sign up for a free SpacDesk account at spacdesk.com.